MedTrace Logo

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

NCT01091259 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2015-11-24

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the efficacy and toxicity of irinotecan in the treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when combined with bevacizumab.

Conditions

Interventions

DRUG

Irinotecan

DRUG

Bevacizumab

Sponsors & Collaborators

Principal Investigators

  • Franco Muggia, MD · New York Unviersity Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2014-02-28
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01091259 on ClinicalTrials.gov